VIVEX Biologics’ Post

Don't Miss out!!! BC Insider's June Newsletter will be sent out in one week - so sign up today for your guide to Biologics, Specialty Medications and Access Solutions. Sign up today for exclusive insights with the link below: https://lnkd.in/ebN795FC #BCInsider #BCEducators #BiologicCoordinator #BiologicAccess #AccessSolutions

LENZ Therapeutics plans to seek FDA approval for its investigational eye drops for #presbyopia, setting up the drug to compete against AbbVie’s #Vuity and Orasis Pharmaceuticals’ #Qlosi. The biopharma recently shared positive Phase 3 data for two formulations of the treatment, saying both met the study’s primary endpoint, though it plans to pursue an #NDA for the version that doesn’t include #brimonidine. In topline data from the CLARITY 1 and 2 trials, LENZ investigated two formulations of #aceclidine: LNZ100 and LNZ101, which contains brimonidine. In the CLARITY 2 trial, LNZ100 won out, with 71% of patients achieving three lines or greater improvement in eyesight after 30 minutes based on the Best Corrected Distance Visual Acuity test. LNZ100 hit the primary endpoint, with 71% of patients achieving three lines or greater improvement in eyesight after 3 hours. About 40% of patients who received that formulation achieved three lines or greater improvement after 10 hours. https://bit.ly/4cISDq9

Our research effort is focused on finding effective pharmaceutical agents as hemostatic adjuncts for pre-hospital resuscitation to improve survival following traumatic hemorrhage https://lnkd.in/gEVhdUWt

The pharmaceutical landscape is witnessing a significant shift! GLP-1 medications, such as Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic, are set to become the top-selling drug class of 2024, overtaking PD-1 inhibitors. With projected sales nearing $50 billion, GLP-1s are rapidly becoming the cornerstone of treatments for metabolic disorders and beyond. Laxxon Medical is joining the weight loss drug development initiative with an oral GLP-1 Agonist treatment, LXM.2. You can learn more about our GLP-1 project, LXM.2, here: https://lnkd.in/dDT93dca Explore the dynamics fueling the weight loss market growth and what it means for the future of medical treatments: https://lnkd.in/gHgNdEMJ #pharmaceutical #3dprinting #medicalinnovation #medicaltechnology #SPID #LaxxonMedical #3DSP #InnovateWithUs

When you have more than 30B data points, you can see what patients taking Repatha, Trulicity and other biologics say about adherence rates and more. Download (free): https://lnkd.in/ebn5pS5g #Pharma #PatientSupport

From rapid drug absorption to ease of use for patients, there are many reasons to consider developing an inhaled medicine. With our expanded inhalation study capacity in the U.S. and U.K., you can explore new potentials for your pharmaceutical product, possibly extending its lifespan and patient reach. Learn more about our inhalation testing capabilities and book your study today: https://lnkd.in/gEyMMKph #InhalationToxicology #InhalationMedicine #QuickStudyStarts

Learn about innovative capping strategies to boost potency, cut costs, and expedite the production of your mRNA programs! Join us on March 27 together with Pharmaceutical Technology for an exciting webinar delving into the crucial role of 5’ cap structures in #mRNA stability and expression. https://lnkd.in/g2tJ3rWM

Clinical decision-making is changing. We've outlined four predictions for the next decade, and what that means for medical device and pharmaceutical companies. Download the full report now ⤵️ http://spr.ly/6042u0tAi

BSI Medicinal & Biologics Team has just released the Medicinal Dossier Guidance. Take a look at our webpage to discover more on devices which incorporate an ancillary medicinal substance and fall under MDR Rule 14. https://lnkd.in/eZ7xdXea #BSI #MedicalDevices #MedicinalandBiologics #MedicinalDossier #MDRRule14 #AncillaryMedicinalSubstances

From rapid drug absorption to ease of use for patients, there are many reasons to consider developing an inhaled medicine. With our expanded inhalation study capacity in the U.S. and U.K., you can explore new potentials for your pharmaceutical product, possibly extending its lifespan and patient reach. Learn more about our inhalation testing capabilities and book your study today: https://lnkd.in/e9jwz3wP #InhalationToxicology #InhalationMedicine #QuickStudyStarts